Dear Editor, we read the publication on "The synergistic effect between adult weight changes and CYP24A1 polymorphisms is associated with pre-and postmenopausal breast cancer (BC) risk" with great interest [1] . Cao et al. noted that "Significant interactions of weight change with CYP24A1 polymorphisms suggest CYP24A1 as a potential link between weight change and BC risk [1] ." Indeed, there are several factors that are associated with BC risk. Regarding the effect of CYP24A1 polymorphisms, single mutations were studied by Cao et al. The pathogenesis of studied CYP24A1 polymorphisms is molecular change due to mutation. Based on the standard molecular calculation technique, as mentioned in previous publications [2], the molecular weight changes in C/T and A/G variants are equal to + 15 (from 111.1 to 126.1) and + 16 ( from 135.1 to 151.1) g/Mol, respectively. Nevertheless, there are also other possible genetic polymorphisms that are related to BC risk. The examples are ACVB1 and AGER polymorphisms [3, 4] . The effects of other additional confounding factors should be assessed in future studies.
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